Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
Roberto Badagliacca, Susanna Sciomer, Nicola Petrosillo
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)PneumoniaPulmonary hypertensionCoronavirusEndothelin receptorImmune systemEndothelin 1Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDiseaseImmunologyCardiologyIntensive care medicineInternal medicineReceptorPathologyInfectious disease (medical specialty)OutbreakInflammasome and immune disordersNeutrophil, Myeloperoxidase and Oxidative MechanismsPulmonary Hypertension Research and Treatments